☰

Jeremy D. Waight, Ph.D. - Publications

Affiliations: 
2012 Microbiology and Immunology State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Immunology, Molecular Biology, Oncology
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Worboys JD, Vowell KN, Hare RK, Ambrose AR, Bertuzzi M, Conner MA, Patel FP, Zammit WH, Gali-Moya J, Hazime KS, Jones KL, Rey C, Jonjic S, Rovis TL, Tannahill GM, ... ... Waight JD, et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nature Communications. 14: 5016. PMID 37596248 DOI: 10.1038/s41467-023-40755-3  0.303
2023 Yadavilli S, Waight JD, Brett S, Bi M, Zhang T, Liu YB, Ellis C, Turner DC, Hahn A, Shi H, Seestaller-Wehr L, Jing J, Xie Q, Shaik JS, Ji X, et al. Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Research Communications. 3: 1564-1579. PMID 37593752 DOI: 10.1158/2767-9764.CRC-22-0293  0.41
2022 Alsaid H, Cheng SH, Bi M, Xie F, Rambo M, Skedzielewski T, Hoang B, Mohanan S, Comroe D, Gehman A, Hsu CY, Farhangi K, Tran H, Sherina V, Doan M, ... ... Waight JD, et al. Immuno-PET Monitoring of CD8 T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a Zr Anti-CD8 Mouse Minibody in EMT6 Syngeneic Tumor Mouse. Molecular Imaging and Biology. PMID 36266600 DOI: 10.1007/s11307-022-01781-7  0.391
2020 Dubuisson A, Fahrner JE, Goubet AG, Terrisse S, Voisin N, Bayard C, Lofek S, Drubay D, Bredel D, Mouraud S, Susini S, Cogdill A, Rebuffet L, Ballot E, Jacquelot N, ... ... Waight JD, et al. Immunodynamics of explanted human tumors for immuno-oncology. Embo Molecular Medicine. e12850. PMID 33372722 DOI: 10.15252/emmm.202012850  0.366
2020 Waight JD, Bi M, Kilian D, Hopson C, Zhang S, Brett S, Yadavilli S, Zhang T, Shi H, Hance KW, Ballas M, Hoos A. Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies Immunology. DOI: 10.1158/1538-7445.Am2020-2220  0.441
2019 Waight J, Manrique M, Gombos R, Costa M, Iyer P, Vincent S, Ward R, Paltrinieri E, Chand D, Wilson N, Buell J, Savitsky D. Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies. Journal of Clinical Oncology. 37: e14126-e14126. DOI: 10.1200/Jco.2019.37.15_Suppl.E14126  0.468
2019 Chand D, Waight JD, Paltrinieri E, Dietrich S, Bushell M, Costa M, Gombos R, Wilson NS, Buell JS, Stein RB, Duncan A, Savitsky DA. Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses Cancer Research. 79: 2390-2390. DOI: 10.1158/1538-7445.Am2019-2390  0.532
2018 Waight JD, Chand D, Savitsky DA. New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy. Oncotarget. 9: 31171-31172. PMID 30131845 DOI: 10.18632/Oncotarget.25800  0.352
2018 Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, Manrique M, Swiech L, Morin B, Brittsan C, Tanne A, Akpeng B, Croker BA, Buell JS, Stein R, et al. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer Cell. 33: 1033-1047.e5. PMID 29894690 DOI: 10.1016/J.Ccell.2018.05.005  0.472
2018 Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, Breous-Nystrom E, Dupont C, Ward RA, Mundt C, Duckless B, Tang H, Findeis MA, Schuster A, Waight JD, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. Plos One. 13: e0191926. PMID 29617360 DOI: 10.1371/Journal.Pone.0191926  0.517
2018 Waight J, Iyer P, Breous-Nystrom E, Riordan C, Findeis M, Underwood D, Connolly J, Sanicola-Nadel M, Nastri H, Scherle P, Hollis G, Huber R, Stein R, Dijk Mv, Wilson NS. Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3 Cancer Research. 78: 3825-3825. DOI: 10.1158/1538-7445.Am2018-3825  0.538
2018 Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, Manrique M, Tanne A, Dupont C, Swiech L, Croker BA, Buell JS, Stein R, Duncan A, Savitsky DA, et al. Abstract 2721: Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity Cancer Research. 78: 2721-2721. DOI: 10.1158/1538-7445.Am2018-2721  0.5
2017 Waight JD, Gombos RB, Wilson NS. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities. Human Antibodies. PMID 28085016 DOI: 10.3233/Hab-160308  0.503
2017 Gonzalez AM, Manrique ML, Swiech L, Horn T, Breous E, Waight J, Savitsky D, Liu Y, Lin S, Clarke C, Merghoub T, Hirschhorn-Cymerman D, Schaer D, Ritter G, Pulini J, et al. Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells Cancer Research. 77: 4703-4703. DOI: 10.1158/1538-7445.Am2017-4703  0.548
2017 Drouin EE, Savitsky D, Gonzalez AM, Gombos R, Chand D, Waight J, Yang X, Khattar M, Morin B, Findeis M, Schaer D, Merghoub T, Ritter G, Tanne A, Dijk Mv, et al. Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model Cancer Research. 77: 3654-3654. DOI: 10.1158/1538-7445.Am2017-3654  0.426
2017 Gonzalez AM, Manrique ML, Swiech L, Horn T, Waight J, Liu Y, Lin S, Underwood D, Breous E, Leger O, Seibert V, Merghoub T, Zappasodi R, Ritter G, Schaer D, et al. Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization Cancer Research. 77: 3643-3643. DOI: 10.1158/1538-7445.Am2017-3643  0.525
2016 Drouin EE, Gonzalez A, Tang H, Savitsky D, Gombos R, Waight J, Duckless B, Schuster A, Wang L, Lin S, Mundt C, Ritter G, Merghoub T, Draleau K, Wolchok J, et al. Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies Cancer Research. 76: 5005-5005. DOI: 10.1158/1538-7445.Am2016-5005  0.501
2016 Gonzalez AM, Breous E, Manrique ML, Savitsky D, Waight J, Gombos R, Liu Y, Lin S, Leger O, Seibert V, Tsuji T, Merghoub T, Budha S, Zappasodi R, Ritter G, et al. Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR Cancer Research. 76: 3220-3220. DOI: 10.1158/1538-7445.Am2016-3220  0.56
2016 Gonzalez AM, Manrique ML, Breous E, Savitsky D, Waight J, Gombos R, Liu Y, Lin S, Merghoub T, Hirschhorn-Cymerman D, Ritter G, Wolchok J, Scherle P, Hollis G, Huber R, et al. Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells Cancer Research. 76: 3204-3204. DOI: 10.1158/1538-7445.Am2016-3204  0.589
2015 Waight JD, Hofmeister R, Wilson NS. Response to comment on "cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans". Journal of Immunology (Baltimore, Md. : 1950). 194: 3533-4. PMID 25848069 DOI: 10.4049/Jimmunol.1500367  0.492
2015 Waight JD, Takai S, Marelli B, Qin G, Hance KW, Zhang D, Tighe R, Lan Y, Lo KM, Sabzevari H, Hofmeister R, Wilson NS. Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans. Journal of Immunology (Baltimore, Md. : 1950). 194: 878-82. PMID 25548231 DOI: 10.4049/Jimmunol.1402725  0.537
2014 Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. The Journal of Biological Chemistry. 289: 15642-52. PMID 24753251 DOI: 10.1074/Jbc.M113.544320  0.544
2013 Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, Repasky EA. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proceedings of the National Academy of Sciences of the United States of America. 110: 20176-81. PMID 24248371 DOI: 10.1073/Pnas.1304291110  0.591
2013 Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. The Journal of Clinical Investigation. 123: 4464-78. PMID 24091328 DOI: 10.1172/Jci68189  0.619
2012 Abrams SI, Waight JD. Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. Oncoimmunology. 1: 550-551. PMID 22754783 DOI: 10.4161/Onci.19334  0.613
2011 Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. Plos One. 6: e27690. PMID 22110722 DOI: 10.1371/Journal.Pone.0027690  0.613
Show low-probability matches.